![Quiver Logo](/static/img/logo-icon.png)
![CNTX logo](https://quiver-logos.s3.us-east-2.amazonaws.com/cntx.png)
Context Therapeutics Inc. Common Stock
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CNTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of CNTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CNTX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to CNTX
Recent picks made for CNTX stock on CNBC
ETFs with the largest estimated holdings in CNTX
Flights by private jets registered to CNTX
![Quiver Logo](/static/img/logo-icon.png)